Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 11/2/20 → 7/26/26 |
Funding
- PDS Biotechnology: $175,199.00
A Phase II, Open-Label, Multi-Center Study of PDS0101 (ImmunoMAPK -RDOTAP/HPV-16 E6 & E7 Peptides) and Pembrolizumab (KEYTRUDA) Combination Immunotherapy as a First Line Treatment in Subjects with Recurrent
- Arnold, Susanne M (PI)
- Kejner, Alexandra (Former PI)
- Zinner, Ralph (Former PI)